Kenichi Takeshita
Celgene
49 Papers
537 Citations
Kenichi Takeshita is an academic researcher from Celgene. The author has contributed to research in topics: Lenalidomide & Non-Hodgkin's lymphoma. The author has an hindex of 18, co-authored 42 publications. Previous affiliations of Kenichi Takeshita include Roswell Park Cancer Institute & University of Miami.
Chat about Author
Papers
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
Peter H. Wiernik,Izidore S. Lossos,Joseph Tuscano,Glen Justice,Julie M. Vose,Craig E. Cole,Wendy Yin Han Lam,Kyle McBride,Kenton Wride,Dennis Pietronigro,Kenichi Takeshita,Annette Ervin-Haynes,Jerome B. Zeldis,Thomas M. Habermann +13 more
TL;DR: Oral lenalidomide monotherapy is active in relapsed or refractory aggressive NHL, with manageable side effects, in a phase II, single-arm, multicenter trial.
402
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
Ahmed I. Younes,Patrick Hilden,Bertrand Coiffier,Anton Hagenbeek,Gilles Salles,Walter R. Wilson,John F. Seymour,Kara M. Kelly,John G. Gribben,M Pfreunschuh,Franck Morschhauser,Heiko Schöder,Andrew D. Zelenetz,Jürgen Rademaker,Ranjana H. Advani,Nancy Valente,Catherine Fortpied,T. E. Witzig,Laurie H. Sehn,Andreas Engert,Richard I. Fisher,Pier Luigi Zinzani,Massimo Federico,Martin Hutchings,Catherine M. Bollard,Marek Trneny,Yusri Elsayed,Kensei Tobinai,Jeremy S. Abramson,Nathan Fowler,Andre Goy,Mitchell R. Smith,S. M. Ansell,John Kuruvilla,Martin Dreyling,Catherine Thieblemont,Richard F. Little,Igor Aurer,M. H. J. Van Oers,Kenichi Takeshita,Ajay K. Gopal,Simon Rule,S. de Vos,Ioana Kloos,Mark S. Kaminski,Michel Meignan,Lawrence H. Schwartz,John P. Leonard,Stephen J. Schuster,Venkatraman E. Seshan +49 more
TL;DR: It is demonstrated that assessment of tumor burden in lymphoma clinical trials can use the sum of longest diameters of a maximum of three target lesions, and a new lymphoma response criteria (RECIL 2017) was developed.
331
STAT3 is a negative regulator of granulopoiesis but is not required for G-CSF-dependent differentiation.
Chien-Kuo Lee,Regina Raz,Ramon Gimeno,Rachel Gertner,Birte Wistinghausen,Kenichi Takeshita,Ronald A. DePinho,David E. Levy +7 more
TL;DR: These studies provide direct evidence for STAT3-independent granulopoiesis and suggest that STAT3 directs a negative feedback loop necessary for controlling neutrophil numbers, possibly through induced expression of the signaling inhibitor, SOCS3.
268
Results of a phase 1 clinical trial of thalidomide in combination with fludarabine as initial therapy for patients with treatment-requiring chronic lymphocytic leukemia (CLL).
Asher A. Chanan-Khan,Kena C. Miller,Kena C. Miller,Kena C. Miller,Kenichi Takeshita,Kenichi Takeshita,Kenichi Takeshita,Alexandra Koryzna,Alexandra Koryzna,Alexandra Koryzna,Kathleen Donohue,Kathleen Donohue,Kathleen Donohue,Zale P. Bernstein,Zale P. Bernstein,Zale P. Bernstein,Alice Mohr,Alice Mohr,Alice Mohr,Donald Klippenstein,Donald Klippenstein,Donald Klippenstein,Paul K. Wallace,Paul K. Wallace,Paul K. Wallace,Jerome B. Zeldis,Jerome B. Zeldis,Jerome B. Zeldis,Christine Berger,Christine Berger,Christine Berger,Myron S. Czuczman,Myron S. Czuczman,Myron S. Czuczman +33 more
TL;DR: Thalidomide given up to 300 mg/day concurrently with fludarabine in patients with previously untreated CLL shows encouraging clinical efficacy and acceptable toxicity, and an ongoing phase 2 study will help validate the clinical efficacy of this regimen.
106
Effect of Highly Active Antiretroviral Therapy on Survival in Patients With AIDS-Associated Pulmonary Kaposi’s Sarcoma Treated With Chemotherapy
Beata Holkova,Kenichi Takeshita,Debbie M. Cheng,Matthew Volm,Carolyn Wasserheit,Rita I. Demopoulos,Asher Chanan-Khan +6 more
TL;DR: In patients with AIDS-associated PKS and undergoing chemotherapy, administration of HAART was associated with increased survival and Cox multivariate analyses indicated that patients on HAART had substantially better survival.
97